Sophiris Bio, Inc. SPHS OTC

Sophiris Bio, Inc. (SPHS) reported total assets of $13.2M and total liabilities of $11.46M for fiscal year 2018, resulting in total equity of $1.74M.

The company held $12.54M in cash and short-term investments. Total debt stood at $7.01M, with net debt of $-3.99M. The Debt-to-Equity (D/E) ratio was 4.04 (leveraged).

Current ratio is 2.65, indicating strong short-term liquidity. Interest coverage is -8.9x (weak).

Criteria supported by this page:

• HEALTH (33/100, Fail) — the balance sheet shows elevated risk in debt or liquidity metrics
• MOAT (28/100) — Total assets $13.2M and equity $1.74M support the company's competitive scale

Overall SharesGrow Score: 49/100 with 2/7 criteria passed.

LLY

Eli Lilly and Company

$922.50

-0.76%

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%

RHHBF

Roche Holding AG

$418.50

+1.82%

RHHBY

Roche Holding AG

$51.02

+0.65%

AZN

AstraZeneca PLC

$204.38

+1.06%

NVSEF

Novartis AG

$156.48

+0.00%

MRK

Merck & Co., Inc.

$119.96

-0.16%